Company REGENXBIO Inc.

Equities

RGNX

US75901B1070

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for REGENXBIO Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
12.71 ^USD	+18.34%		+17.47%	-29.19%

Jun. 24	Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial	MT
Jun. 24	REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients	CI

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Number of employees: 344

USD in Million	2022	Weight	2023	Weight	Delta
Gene Therapy 100.0 %	113	100.0 %	90	100.0 %	-19.94%

USD in Million	2022	Weight	2023	Weight	Delta
International 68.0 %	62	55.0 %	61	68.0 %	-1.02%
United States 32.0 %	39	35.0 %	29	32.0 %	-26.81%

Managers	Title	Age	Since
Curran Simpson CEO	Chief Executive Officer	62	15-07-31
Vit Vasista DFI	Director of Finance/CFO	56	09-07-31
Kenneth Mills CHM	Chairman	49	08-07-15
Jerome W. Jackson CTO	Chief Tech/Sci/R&D Officer	-	15-10-31
Olivier Danos CTO	Chief Tech/Sci/R&D Officer	66	17-03-27
Stephen Pakola CTO	Chief Tech/Sci/R&D Officer	55	19-04-16
Shiva G. Fritsch IRO	Public Communications Contact	-	16-12-31
Laura Coruzzi PRN	Corporate Officer/Principal	71	-
Ram Palanki PRN	Corporate Officer/Principal	48	18-07-31
Patrick Christmas LAW	General Counsel	53	16-07-31

Members of the board	Title	Age	Since
George Migausky BRD	Director/Board Member	69	21-09-02
David Stump BRD	Director/Board Member	74	15-10-14
Argeris Karabelas BRD	Director/Board Member	71	15-04-30
Curran Simpson CEO	Chief Executive Officer	62	15-07-31
Daniel Tassé BRD	Director/Board Member	64	16-08-14
Alexandra Glucksmann BRD	Director/Board Member	65	18-05-24
Allan Fox FOU	Founder	76	08-12-31
Kenneth Mills CHM	Chairman	49	08-07-15
Jennifer Zachary BRD	Director/Board Member	46	22-06-02
Jean Bennett BRD	Director/Board Member	69	21-02-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,255,966	45,650,865 ( 92.68 %)	0	92.68 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.58 %	7,182,401	14.58 %	84 M $
Vanguard Fiduciary Trust Co. 9.901 %	4,876,881	9.901 %	57 M $
Redmile Group LLC 9.241 %	4,551,556	9.241 %	53 M $
JPMorgan Investment Management, Inc. 7.558 %	3,722,553	7.558 %	44 M $
STATE STREET CORPORATION 6.340 %	3,122,639	6.340 %	37 M $
FOXKISER LLP 5.852 %	2,882,466	5.852 %	34 M $
Morgan Stanley Investment Management, Inc. 2.720 %	1,339,838	2.720 %	16 M $
Avidity Partners Management LP 2.639 %	1,300,064	2.639 %	15 M $
DFA Australia Ltd. 2.272 %	1,119,109	2.272 %	13 M $
GIC Pte Ltd. (Investment Management) 2.116 %	1,042,011	2.116 %	12 M $

REGENXBIO, Inc.

9804 Medical Center Drive

20850, Rockville

+240 552 8181

http://www.regenxbio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.71 USD

Average target price

40.55 USD

Spread / Average Target

+219.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENXBIO INC.	-29.19%	626M
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B
REGENERON PHARMACEUTICALS, INC.	+23.00%	117B
ARGENX SE	+25.15%	27.77B
BIONTECH SE	-19.75%	20.44B
GENMAB A/S	-16.57%	16.62B
BEIGENE, LTD.	-16.56%	15.92B
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.74B
WUXI APPTEC CO., LTD.	-46.65%	14.94B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs